Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 5/20 | 0.80 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.80 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414525 | 1.00 | OXTR (0.80) | OXTRAVPR1APOLBMEN1KMT2A | |
| SCHEMBL4415041 | 1.00 | OXTR (0.80) | OXTRAVPR1APOLBMEN1KMT2A | |
| SCHEMBL4417747 | 1.00 | OXTR (0.80) | OXTRAVPR1APOLBMEN1KMT2A | |
| SCHEMBL31155974 | 0.93 | OXTR (0.76) | OXTRAVPR1AMEN1KMT2AALDH1A1 | |
| SCHEMBL6449338 | 0.91 | OXTR (0.67) | OXTRAVPR1APOLBMEN1KMT2A | |
| SCHEMBL4418576 | 0.91 | OXTR (0.67) | OXTRAVPR1APOLBMEN1KMT2A | |
| SCHEMBL4418573 | 0.91 | OXTR (0.67) | OXTRAVPR1APOLBMEN1KMT2A | |
| SCHEMBL4416652 | 0.91 | OXTR (0.67) | OXTRAVPR1APOLBMEN1KMT2A | |
| SCHEMBL4416654 | 0.91 | OXTR (0.67) | OXTRAVPR1APOLBMEN1KMT2A | |
| SCHEMBL8314834 | 0.91 | OXTR (0.67) | OXTRAVPR1APOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532109-B1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK SERONO SA (CH) | 2009-09-09 | — | — | EP | claimed |
| US-7115754-B2 | Pyrrolidine derivatives as oxytocin antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-10-03 | — | — | US | claimed |
| US-20060004020-A1 | Pyrrolidine derivatives as oxytocin antagonists | MERCK SERONO SA (CH) | 2006-01-05 | — | — | US | claimed |
| EP-1532109-B1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK SERONO SA (CH) | 2009-09-09 | — | — | EP | disclosed |
| US-7115754-B2 | Pyrrolidine derivatives as oxytocin antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-10-03 | — | — | US | disclosed |
| US-20060004020-A1 | Pyrrolidine derivatives as oxytocin antagonists | MERCK SERONO SA (CH) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004020-A1 | Pyrrolidine derivatives as oxytocin antagonists | OXTR, PRLHR, AVPR1A | OXTR 1/4885AVPR1A 3/4885POLB 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.